Mizuho restated their buy rating on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a report issued on Friday.

Several other brokerages have also recently weighed in on GILD. ValuEngine raised shares of Gilead Sciences from a buy rating to a strong-buy rating in a research note on Thursday, September 7th. TheStreet raised shares of Gilead Sciences from a c+ rating to a b- rating in a research note on Thursday, September 7th. Zacks Investment Research cut shares of Gilead Sciences from a buy rating to a hold rating in a research note on Monday, September 11th. Vetr cut shares of Gilead Sciences from a buy rating to a hold rating and set a $86.44 price objective on the stock. in a research note on Monday, September 4th. Finally, Wells Fargo & Company boosted their price objective on shares of Gilead Sciences from $73.00 to $81.00 and gave the stock a market perform rating in a research note on Wednesday, September 6th. Eleven analysts have rated the stock with a hold rating and twenty have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $84.29.

Gilead Sciences (GILD) traded up 0.14% on Friday, hitting $81.02. The stock had a trading volume of 13,301,278 shares. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $86.27. The company has a market capitalization of $105.81 billion, a PE ratio of 8.80 and a beta of 1.19. The company has a 50 day moving average of $77.54 and a 200 day moving average of $70.38.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter in the previous year, the firm posted $3.08 earnings per share. Gilead Sciences’s revenue for the quarter was down 8.2% on a year-over-year basis. On average, equities analysts expect that Gilead Sciences will post $8.78 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This article was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/09/30/gilead-sciences-inc-gild-receives-buy-rating-from-mizuho.html.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Shareholders of record on Friday, September 15th were paid a $0.52 dividend. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $2.08 annualized dividend and a yield of 2.57%. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.

In other news, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total transaction of $355,300.00. Following the completion of the sale, the executive vice president now owns 102,988 shares in the company, valued at approximately $7,318,327.28. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $227,197,799. The disclosure for this sale can be found here. In the last quarter, insiders sold 466,819 shares of company stock valued at $36,740,240. Company insiders own 1.30% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Seizert Capital Partners LLC increased its stake in shares of Gilead Sciences by 4.6% during the 1st quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock worth $42,964,000 after purchasing an additional 27,547 shares during the last quarter. Linscomb & Williams Inc. increased its stake in shares of Gilead Sciences by 3.0% during the 1st quarter. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company’s stock worth $358,000 after purchasing an additional 154 shares during the last quarter. Sigma Planning Corp increased its stake in shares of Gilead Sciences by 7.7% during the 1st quarter. Sigma Planning Corp now owns 40,168 shares of the biopharmaceutical company’s stock worth $2,728,000 after purchasing an additional 2,889 shares during the last quarter. Investment Centers of America Inc. increased its stake in shares of Gilead Sciences by 7.2% during the 1st quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock worth $1,979,000 after purchasing an additional 1,958 shares during the last quarter. Finally, HealthInvest Partners AB increased its stake in shares of Gilead Sciences by 3.5% during the 1st quarter. HealthInvest Partners AB now owns 117,000 shares of the biopharmaceutical company’s stock worth $7,947,000 after purchasing an additional 4,000 shares during the last quarter. Institutional investors own 73.97% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.